Rejected from Molecular Psychiatry? Where to Submit Next

The useful question is not "which psychiatry journal is easier?" It is "what did Molecular Psychiatry not believe about this manuscript?"

If the editor did not believe the manuscript had enough psychiatric relevance, the next journal may be neuroscience, genetics, molecular biology, or biomarker-methods focused. If the editor believed the psychiatric question mattered but the mechanism was thin, the next target may be clinical psychiatry. If reviewers questioned medication exposure, diagnostic heterogeneity, cohort definition, replication, sample size, statistical adjustment, or translational overreach, those problems travel with the paper.

Use the decision letter to classify the failure:

Molecular Psychiatry is not a general psychiatry journal with a molecular label. The source-backed fit screen is different. The journal's public positioning points toward biological mechanisms underlying psychiatric disorders and treatment. Its preparation guidance also requires a concise, evidence-forward package, including a single-paragraph abstract and clear methods detail. Nature's how-to-submit page says manuscript submissions are accepted only through the online manuscript submission system, so authors can track status online, but the portal mechanics do not solve the fit problem.

That makes the rejection diagnostically useful. It often means one of three things:

• The paper is good psychiatry but too clinically descriptive. A cohort, treatment, symptom, or service-delivery study can matter, but Molecular Psychiatry needs a convincing biological or translational mechanism.
• The paper is good neuroscience but not psychiatric enough. A molecular, circuit, imaging, animal, or genetics paper may be strong, but the psychiatric disorder or treatment consequence may feel attached late.
• The evidence bridge is unstable. The manuscript may jump from association to mechanism, from animal model to human treatment, from biomarker to diagnosis, or from subgroup signal to disorder-level claim.

This is why the next submission should be routed by manuscript phenotype, not by impact-factor adjacency.

This page was researched from Nature Portfolio's Molecular Psychiatry journal page, preparation-of-articles instructions, how-to-submit page, author and referee materials, and Manusights' existing Molecular Psychiatry content cluster. In our analysis of the post-rejection routing job, the non-obvious question is not whether Translational Psychiatry or Biological Psychiatry is "next." It is which manuscript component created the rejection signal: psychiatric phenotype, molecular mechanism, cohort definition, medication exposure, confound adjustment, first figure, statistical model, abstract claim, cover letter, or limitations.

The specific rejection patterns below are written as a diagnostic, not as a generic journal list. We see authors lose time when they interpret a Molecular Psychiatry rejection as a prestige problem, but the paper actually has a psychiatric-identity, mechanism, or evidence-chain problem. In practice, the best next journal is the one where the manuscript's evidence can support its claim without forcing a biology-to-psychiatry bridge that the data cannot carry.

Rebuild for Molecular Psychiatry only when the manuscript still has a strong biology-to-psychiatry claim and the rejection exposed a repairable weakness. This is most plausible after a detailed review, a revision decision, or a desk rejection where the science was strong but the psychiatric identity or mechanism was buried.

Good reasons to rebuild:

• The primary finding links molecular, genetic, circuit, biomarker, cellular, pharmacological, or systems evidence to a psychiatric disorder or treatment in a way that changes understanding.
• The rejection letter questioned framing, reporting completeness, statistical adjustment, confound handling, or fit argument rather than the underlying study.
• Medication exposure, diagnostic heterogeneity, comorbidity, ancestry, batch effects, sample source, or replication can be clarified or repaired.
• The strongest psychiatry-facing consequence was hidden in the discussion instead of visible in the title, abstract, results, first figure, and cover letter.

Bad reasons to rebuild:

• You only want to stay near the Nature Portfolio brand.
• The paper is clinically interesting but biologically thin.
• The paper is mechanistically strong but only loosely connected to psychiatric disorder or treatment.
• The core limitation requires new samples, human validation, replication, or a different experimental design.

If you rebuild, make the correction visible early. A new cover letter cannot rescue a manuscript whose title, abstract, and first figure still read like the wrong journal.

Translational Psychiatry is often the better next route when the paper is rigorous, psychiatry-facing, and biologically informed, but not novel or high-priority enough for Molecular Psychiatry. It can work for studies where the translational bridge is useful but the mechanism is not definitive.

Biological Psychiatry is often the better route when the manuscript has a strong neurobiological, treatment-mechanism, or pathophysiology argument and a clear psychiatric readership. It is a better target than a generic neuroscience journal when the patient, disorder, treatment, or psychiatric phenotype is central rather than incidental.

Choose these routes when the manuscript can answer:

• What psychiatric disorder, phenotype, symptom dimension, treatment response, or patient group does the biology explain?
• Which molecular, genetic, cellular, circuit, pharmacological, imaging, or biomarker evidence supports that explanation?
• Are medication exposure, diagnostic heterogeneity, comorbidity, ancestry, and batch effects handled rather than hidden?
• Does the manuscript make a translational claim it can actually defend?

If the answer is mostly "the biology is interesting," but the psychiatric consequence is weak, choose a neuroscience or molecular biology journal instead.

Many Molecular Psychiatry rejections are strong papers in the wrong lane.

Move toward JAMA Psychiatry, American Journal of Psychiatry, or a clinical psychiatry journal when the manuscript's real contribution is diagnosis, treatment, prognosis, symptoms, population health, health services, risk prediction, or clinical outcomes. The rewrite should reduce molecular overclaiming and make the clinical decision explicit.

Move toward Nature Neuroscience or another neuroscience journal when the contribution is mechanism, circuit biology, molecular pathway, computational model, animal behavior, cellular physiology, or neural systems. The rewrite should stop forcing psychiatric practice relevance if the paper cannot support it.

Move toward genetics, omics, biomarker, or methods journals when the paper's strongest contribution is measurement, discovery, or analytic method. A biomarker association is not automatically a psychiatric practice claim. A polygenic or expression signal is not automatically mechanism. A classifier is not automatically diagnosis.

In our pre-submission and post-decision review work with manuscripts aimed at Molecular Psychiatry, the highest-value repairs are usually not language edits. They are routing and evidence-chain decisions tied to concrete components: title, abstract, psychiatric phenotype, diagnostic criteria, medication exposure, cohort definition, biological assay, statistical model, replication, figure order, cover letter, and limitations.

Three specific rejection patterns are especially common.

The psychiatric-identity gap. The manuscript has strong neuroscience, genetics, omics, or molecular biology, but psychiatric relevance appears late or indirectly. The title names a pathway, region, model, or assay, while the abstract only loosely connects it to depression, schizophrenia, autism, bipolar disorder, addiction, PTSD, or treatment response. The repair is not to add psychiatric keywords. The repair is to show the psychiatric phenotype, disorder logic, patient relevance, or treatment implication that the evidence actually supports.

The mechanism-overclaim gap. The paper reports an association, expression difference, imaging signal, animal behavior, biomarker panel, or model output, then writes as if it has established mechanism. Editors and reviewers notice this quickly because Molecular Psychiatry sits at the mechanism-to-disorder interface. The repair is to separate association, mechanism, prediction, and translation, then choose a journal where that evidence level is acceptable.

The confound-control gap. Psychiatric research is vulnerable to medication exposure, diagnostic heterogeneity, comorbidity, ancestry, substance use, site effects, batch effects, age, sex, and ascertainment bias. A manuscript can have a good biological signal and still fail if those variables are handled late or vaguely. The repair is to put the confound logic where reviewers can audit it: methods, table 1, supplement, sensitivity analyses, and limitations.

The practical lesson is direct: after Molecular Psychiatry rejection, the manuscript should either become a stronger biology-to-psychiatry paper or a more honest paper for a better-matched journal. The worst option is a cosmetic resubmission that preserves the same unsupported translational claim.